Lunai Bioworks (NASDAQ:LNAI) Stock Price Up 9.8% – Should You Buy?

Lunai Bioworks Inc. (NASDAQ:LNAI) shares were up 9.8% during mid-day trading on Friday. The company traded as high as $1.68 and last traded at $1.23. Approximately 846,267 shares traded hands during mid-day trading, an increase of 1,602% from the average session volume of 49,724 shares. The stock had previously closed at $1.12.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Lunai Bioworks in a report on Friday, October 2nd. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, Lunai Bioworks has a consensus rating of “Sell”.

Lunai Bioworks Price Performance

The firm’s 50 day moving average is $2.11 and its 200 day moving average is $2.55. The company has a market capitalization of $5.57 million, a PE ratio of -3.07 and a beta of 0.37.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.